JP2005507947A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507947A5
JP2005507947A5 JP2003541835A JP2003541835A JP2005507947A5 JP 2005507947 A5 JP2005507947 A5 JP 2005507947A5 JP 2003541835 A JP2003541835 A JP 2003541835A JP 2003541835 A JP2003541835 A JP 2003541835A JP 2005507947 A5 JP2005507947 A5 JP 2005507947A5
Authority
JP
Japan
Prior art keywords
phenyl
group
carboxy
optionally
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003541835A
Other languages
English (en)
Japanese (ja)
Other versions
JP4150672B2 (ja
JP2005507947A (ja
Filing date
Publication date
Priority claimed from GB0126511A external-priority patent/GB0126511D0/en
Priority claimed from GB0209882A external-priority patent/GB0209882D0/en
Application filed filed Critical
Priority claimed from PCT/EP2002/012300 external-priority patent/WO2003039544A1/en
Publication of JP2005507947A publication Critical patent/JP2005507947A/ja
Publication of JP2005507947A5 publication Critical patent/JP2005507947A5/ja
Application granted granted Critical
Publication of JP4150672B2 publication Critical patent/JP4150672B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003541835A 2001-11-05 2002-11-04 ナフチリジン誘導体、その製造およびそのホスホジエステラーゼイソ酵素4(pde4)阻害剤としての使用 Expired - Lifetime JP4150672B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126511A GB0126511D0 (en) 2001-11-05 2001-11-05 Organic compounds
GB0209882A GB0209882D0 (en) 2002-04-30 2002-04-30 Organic compounds
PCT/EP2002/012300 WO2003039544A1 (en) 2001-11-05 2002-11-04 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors

Publications (3)

Publication Number Publication Date
JP2005507947A JP2005507947A (ja) 2005-03-24
JP2005507947A5 true JP2005507947A5 (cg-RX-API-DMAC7.html) 2005-11-17
JP4150672B2 JP4150672B2 (ja) 2008-09-17

Family

ID=26246741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541835A Expired - Lifetime JP4150672B2 (ja) 2001-11-05 2002-11-04 ナフチリジン誘導体、その製造およびそのホスホジエステラーゼイソ酵素4(pde4)阻害剤としての使用

Country Status (25)

Country Link
US (1) US7273875B2 (cg-RX-API-DMAC7.html)
EP (1) EP1443925B8 (cg-RX-API-DMAC7.html)
JP (1) JP4150672B2 (cg-RX-API-DMAC7.html)
KR (1) KR100623548B1 (cg-RX-API-DMAC7.html)
CN (1) CN1298324C (cg-RX-API-DMAC7.html)
AR (1) AR037517A1 (cg-RX-API-DMAC7.html)
AT (1) ATE349209T1 (cg-RX-API-DMAC7.html)
BR (1) BR0213877A (cg-RX-API-DMAC7.html)
CA (1) CA2462211C (cg-RX-API-DMAC7.html)
CY (1) CY1107532T1 (cg-RX-API-DMAC7.html)
DE (1) DE60217160T2 (cg-RX-API-DMAC7.html)
DK (1) DK1443925T3 (cg-RX-API-DMAC7.html)
ES (1) ES2275935T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0402311A3 (cg-RX-API-DMAC7.html)
IL (2) IL161257A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04004264A (cg-RX-API-DMAC7.html)
MY (1) MY130622A (cg-RX-API-DMAC7.html)
NO (1) NO329093B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532586A (cg-RX-API-DMAC7.html)
PE (1) PE20030535A1 (cg-RX-API-DMAC7.html)
PL (1) PL368286A1 (cg-RX-API-DMAC7.html)
PT (1) PT1443925E (cg-RX-API-DMAC7.html)
RU (1) RU2296764C2 (cg-RX-API-DMAC7.html)
TW (1) TWI320784B (cg-RX-API-DMAC7.html)
WO (1) WO2003039544A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2013211B1 (en) 2006-04-21 2012-03-14 Novartis AG Purine derivatives for use as adenosin a2a receptor agonists
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
EP2482798A1 (en) * 2009-10-01 2012-08-08 Alcon Research, Ltd. Olopatadine compositions and uses thereof
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AU2011278279C1 (en) 2010-07-14 2014-11-27 Novartis Ag IP receptor agonist heterocyclic compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ip受體激動劑之雜環化合物
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
CN103969300B (zh) * 2013-01-24 2016-08-17 湖北大学 一种识别cgg三核苷酸重复序列的双功能电活性探针、探针的制备及试剂盒
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
JP6505023B2 (ja) 2013-02-19 2019-04-24 ファイザー・インク Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2970212B1 (en) 2013-03-14 2018-04-25 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as pde4 inhibitors
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106146491B (zh) * 2015-03-27 2017-12-12 沈阳三生制药有限责任公司 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
CN113423435A (zh) 2018-12-28 2021-09-21 雷杰纳荣制药公司 使用花生四烯酸15-脂氧合酶(alox15)抑制剂治疗呼吸系统病症
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN110339192A (zh) * 2019-08-22 2019-10-18 吉林大学 一种掌叶防己碱用于治疗急性肺损伤的实验方法
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
EP3805206A1 (en) * 2019-10-08 2021-04-14 Novaled GmbH Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
JP2002114684A (ja) 2000-10-03 2002-04-16 Eisai Co Ltd 尿路疾患治療剤

Similar Documents

Publication Publication Date Title
JP2005507947A5 (cg-RX-API-DMAC7.html)
CA2462211A1 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
CA2832996C (en) Tricyclic triazole compounds and their use as aldosterone synthase inhibitors
EP3760629A1 (en) Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
JP2012507566A5 (cg-RX-API-DMAC7.html)
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP2013542261A5 (cg-RX-API-DMAC7.html)
WO2005007081A3 (en) Compounds and methods for delivery of prostacyclin analogs
JP2006509749A5 (cg-RX-API-DMAC7.html)
JP2017527604A5 (cg-RX-API-DMAC7.html)
CN1444478A (zh) 塞利克西组合物在快速缓解疼痛中的用途
JP2004517128A5 (cg-RX-API-DMAC7.html)
CA2902987A1 (en) Benzyl-substituted pyrazolopyridines and use thereof
JP2010516701A5 (cg-RX-API-DMAC7.html)
WO2012075253A3 (en) Pharmaceutical compositions
JP2010516700A5 (cg-RX-API-DMAC7.html)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
CA2626477A1 (en) Dicarboxylic acid derivatives and their use
JP2017513824A5 (cg-RX-API-DMAC7.html)
JP2009513713A5 (cg-RX-API-DMAC7.html)
WO2023169572A1 (zh) 一种三嗪类化合物、其中间体、其制备方法及其用途
JP2011088923A (ja) ピラゾロナフチリジン誘導体
JP7016853B2 (ja) sGC刺激剤のリンプロドラッグ
JPS58194887A (ja) 1,8−ナフチリジンおよび1,5,8−アザナフチリジン誘導体類
JP2008511592A5 (cg-RX-API-DMAC7.html)